Adicet Bio Q2 net loss narrows

ACET•2026-08-05

Analyst coverage

The current average analyst rating on the shares is "strong buy", with 6 "strong buy" or "buy" ratings, no "hold" ratings, and no "sell" or "strong sell" ratings.

The average consensus recommendation for the biotechnology and medical research peer group is "buy."

Wall Street's median 12-month price target for Adicet Bio is $22.50, about 144.3% above its August 4 closing price of $9.21.

Pipeline and leadership updates

Adicet expects topline Phase 1 prula-cel data in lupus nephritis (LN) and systemic lupus erythematosus (SLE) in 3Q/2026.

The company plans to start a pivotal prula-cel trial in LN in 2H/2026, pending regulatory clearance.

A regulatory filing for ADI-212 in is expected in , with Phase 1 enrollment to begin in .

Metric	Actual
Q2 Loss Per Share	$1.99
Q2 Net Loss	$21.36 million
Q2 Operating Expenses	$22.3 million
Q2 Operating Income	-$22.3 million

Adicet Bio Q2 net loss narrows

Analyst coverage

Pipeline and leadership updates

Related News

Samsara schedules fiscal Q2 2027 results webcast after market close

OMA says July 2026 passenger traffic rises 3.9% y/y

Allstate Q2 FY26 net income rises 55.9% to $3.24 billion; revenue climbs 11.8% to $18.6 billion

Q2 loss narrows as R&D spending rises

News Corp FY26 net income from continuing operations rises 15% to $743 million; revenue increases 7% to $9.03 billion

Chiron Real Estate publishes investor deck outlining portfolio transition toward senior housing operating assets